This is a purely administrative filing to add proxy-required disclosures. No financial restatement, no material weakness, and no change to the company's reported results. Monitor the next quarterly filing for any updates on the NetSuite MRP implementation (which missed its 2025 target) and for continued revenue growth trajectory.
Price Chart
Executive Summary
BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation, security ownership, related transactions, and auditor fees) that were omitted from the original filing because the company will not file a definitive proxy statement within 120 days of year-end. No financial statements were amended or restated, and no errors or material weaknesses were disclosed. The filing is administrative in nature and does not change the company's reported financial position or results.
Key Facts
- Amendment adds Part III items (10, 11, 12, 13, 14) that were missing from the original 10-K filed February 26, 2026.
- No financial statements were amended, restated, or revised in this filing.
- The company filed new CEO and CFO certifications under Rule 13a-14(a) as exhibits.
- Revenue for FY2025 was $96.2 million, up 29% from $74.6 million in FY2024.
- GAAP net loss from continuing operations was $12.1 million for FY2025.
- Adjusted EBITDA was $28.1 million (29% of revenue) for FY2025.
- No material weaknesses in internal controls were reported for FY2025.
- CEO Roderick de Greef's total 2025 compensation was $10.47 million.
- Insider ownership by directors and executive officers totals 1,101,103 shares (2.3% of outstanding).
- Five institutional holders each own more than 5%: Casdin Capital (12.2%), BlackRock (11.1%), T. Rowe Price (10.6%), Invesco (8.0%), Vanguard (5.3%).
Financial Impact
No financial impact from this amendment. FY2025 revenue of $96.2M, GAAP net loss of $12.1M, adjusted EBITDA of $28.1M.
Risk Factors
- The NetSuite MRP module implementation was not completed in 2025, resulting in zero payout on that 20% bonus objective.
- Several late Section 16(a) filings were reported by executives and a 10% holder, indicating potential insider trading compliance gaps.
- The company reported a GAAP net loss of $12.1M despite strong revenue growth, driven by $15.5M in IPR&D expense and $21.3M in share-based compensation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001628280-26-028012 |
| Document: blfsfy2025exhibit313.htm | 0001628280-26-028012 |
| Document: blfsfy2025exhibit314.htm | 0001628280-26-028012 |
| Document: 0001628280-26-028012-index-headers.html | 0001628280-26-028012 |
| Document: 0001628280-26-028012-index.html | 0001628280-26-028012 |
| Document: 0001628280-26-028012.txt | 0001628280-26-028012 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | DEFM14A | $35.38 $36.39 | ▲ +2.85% | ▲ +3.97% | $37.22 (+5.20%) |
Jun 3, 2026 17w ago | 8-K | $27.25 $26.66 | ▼ −2.17% | ▲ +1.65% | $37.22 (+36.59%) |
Apr 28, 2026 22w ago | 10-K/A | $19.99 $21.75 | ▲ +8.80% | ▲ +5.69% | $37.22 (+86.19%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▲ +7.44% | ▲ +6.96% | $37.22 (−84.53%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▼ −7.44% | ▼ −6.96% | $37.22 (+84.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access